Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof

US11384153B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Eric Smith · New York, US
• Kara Olson · White Plains, US
• Frank Delfino · Poughquag, US
• David DiLillo · New York, US
• Jessica R. Kirshner · New York, US
• Olga Sineshchekova · Pleasantville, US
• Qian Zhang · Sha Tin, CN

Key dates

• Filing date: Jul 18, 2019
• Grant date: Jul 12, 2022
• Expiry date: Feb 27, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma.